LAVA Therapeutics N.V. Ordinary Shares (LVTX) Dividend History

Company News

• XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

  XOMA Royalty Corporation announced a definitive agreement to acquire LAVA Therapeutics for $1.16-$1.24 per share in cash, plus a contingent value right, with the transaction expected to close in Q4 2025.

  Benzinga

  Featured Companies: XOMA XOMAO XOMAP
• LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

  LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that its CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company is focused on developing its Gammabody platform of bispecific gamma delta T cell engagers for the treatment of solid tumors and hematologic malignancies.

  GlobeNewswire Inc.

  Featured Companies: MRK PFE
• Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

  Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: ETON
• Top Penny Stocks to Buy Now? 3 to Watch as September Ends

  Which penny stocks are you watching right now? The post Top Penny Stocks to Buy Now? 3 to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: ADTX
• Wall Street Breakfast: The Week Ahead (Podcast)

  The Federal Reserve meeting is the big marquee event in the week ahead.

  Seeking Alpha

  Featured Companies: ACB ACN ACVA ADBE AZO BB BSX CBRL CCL COST CRCT CRM DIS DOCN DRI FDX FRPT GIS HAS IDA INCY JPM KBH LMT LW MSFT NKE NWS PRGS PTON RJF SEMR SFIX SNAP SPT SVM T TDUP TMUS V VRCA WMG XPO